Gilead Sciences Inc buy ValueFreak
Start price
30.09.16
/
50%
€70.48
Target price
08.09.26
€98.00
Performance (%)
9.62%
Price
03.05.24
€60.18
Summary
This prediction is currently active. The BUY prediction by ValueFreak shows slight gains of 9.62%. A total of €17.08 was paid as dividends for this prediction. This prediction currently runs until 08.09.26. The prediction end date can be changed by ValueFreak at any time. ValueFreak has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Gilead Sciences Inc | -1.570% | -1.570% | -16.300% | 10.280% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to ValueFreak what are the pros and cons of Gilead Sciences Inc for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Very high dividend yield expected
Top Rating
Very positive Cash Flow expected
High Investments for future growth
Valuable balance sheet
Normal challenges to pay loans and raise capital
ROE higher than 15% per year
Very capable Management
Very good company culture
Leading role in innovation
Strong uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Market Leader or Top 3
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Cons
Comments by ValueFreak for this prediction
In the thread Gilead Sciences Inc diskutieren
Gilead heute mit kursbewegenden Nachrichten
https://investors.gilead.com/news/news-details/2022/Trodelvy-Significantly-Improves-Overall-Survival-in-Pre-Treated-HRHER2--Metastatic-Breast-Cancer-Patients-in-the-TROPiCS-02-Study/default.aspx
https://investors.gilead.com/news/news-details/2022/Trodelvy-Significantly-Improves-Overall-Survival-in-Pre-Treated-HRHER2--Metastatic-Breast-Cancer-Patients-in-the-TROPiCS-02-Study/default.aspx
Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Detailed OS results will be presented at an upcoming medical conference. The safety profile for Trodelvy was consistent with prior studies, and no new safety signals emerged in this patient population.
Bei dem Entwicklungspotential und der aktuellen Bewertung verdient die Aktie mehr Aufmerksamkeit.
Veröffentlichung der Ergebnisse Q4 und Gesamtjahr in der vergangenen Nacht
https://investors.gilead.com/events-and-presentations/events/event-details/2023/Fourth-Quarter--Full-Year-2022-Gilead-Sciences-Earnings-Conference-Call/default.aspx
Es geht auch ohne Veklury wieder aufwärts mit Gilead:
.
Ausblick auf 2023 (aus der Präsentation)
https://investors.gilead.com/events-and-presentations/events/event-details/2023/Fourth-Quarter--Full-Year-2022-Gilead-Sciences-Earnings-Conference-Call/default.aspx
Es geht auch ohne Veklury wieder aufwärts mit Gilead:
.Ausblick auf 2023 (aus der Präsentation)
- FY23 Total Product Sales, excluding Veklury, expected to grow 4 to 6% compared to 2022
- FY23 Veklury Sales expected to be ~$2B, expected to track hospitalization rates and remain highly variable depending on the frequency and severity of surges
- Q123 HIV Sales expected to decline low teens from Q422 reflecting typical seasonality